课题基金 / 基金详情

项目摘要

项目成果

KATHLEEN E. RODGERS的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The molecular mechanisms of immune suppression by two impurities in the organosphosphate pesticides, malathion, acephate and fenitrothion, O,O,S-trimethyl phosphorothioate (OOS-TMP) and O,S,S-trimethyl phosphorodithioate, will be examined. Macrophaages, through cell separation and reconstitution experiments, have been shown to be the lymphoid cell most affected by OOS-TMP treatment. The blockage in the maturation of macrophages which occurs following acute administration of OOS-TMP will be identified. Studies will include changes in macrophage cell surface markers, Ia, Mac-1, Mac-2 and F4/80, functional activity and secretory products. The inhibitory effect of a structural analog OSS-TMP on cytolytic effector function will be examined in detail using functionally defined cytotoxic T lymphocytes (CTL) and other cytolytic effector cells. The site(s) of the blockade of murine CTL function will be determined using conjugate formation and Ca2+ pulse techniques. The molecular sites will be identified using radiolabelled OSS-TMP and biochemical analyses. In addition, an adaptation of a colorimetric assay (dye reduction) for cell viability will be investigated for its suitability as a screening assay for the cytotoxic and cytostatic activities of environmental toxicants. This assay may be an alternative to the standard trypan blue exclusion method for assessing cell viability.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
IND Enabling Studies for RASRx 1902, a novel Mas receptor agonist, for treatment of cognitive impairment in patients at risk for Alzheimer's disease.
  • 批准号:
    10530821
  • 项目类别:
  • 资助金额:
    $38.38万
  • 财政年份:
    2020
  • 负责人:
    KATHLEEN E. RODGERS
  • 依托单位:
IND Enabling Studies for RASRx 1902, a novel Mas receptor agonist, for treatment of cognitive impairment in patients at risk for Alzheimer's disease.
  • 批准号:
    10396541
  • 项目类别:
  • 资助金额:
    $151.56万
  • 财政年份:
    2020
  • 负责人:
    KATHLEEN E. RODGERS
  • 依托单位:
IND Enabling Studies for RASRx 1902, a novel Mas receptor agonist, for treatment of cognitive impairment in patients at risk for Alzheimer's disease.
  • 批准号:
    10644987
  • 项目类别:
  • 资助金额:
    $152.86万
  • 财政年份:
    2020
  • 负责人:
    KATHLEEN E. RODGERS
  • 依托单位:
A(1-7)-Mediated Mitigation of Radiation Induced Thrombocytopenia
  • 批准号:
    8058309
  • 项目类别:
  • 资助金额:
    $43.16万
  • 财政年份:
    2010
  • 负责人:
    KATHLEEN E. RODGERS
  • 依托单位:
海外基金